OncoTherapy Science, Inc. (FRA:30O)

Germany · Delayed Price · Currency is EUR

0.0900

0.00 (0.00%)

Last updated: Feb 23, 2026, 8:20 AM CET

Revenue by Segment

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	Mar '20 Mar 31, 2020	Mar '19 Mar 31, 2019	Mar '18 Mar 31, 2018	Mar '17 Mar 31, 2017	Mar '16 Mar 31, 2016
Pharmaceutical Research and Development and Related Businesses	3.29M	698.00K	9.37M	7.33M	111.05M
Pharmaceutical Research and Development and Related Businesses Growth	370.63%	-92.55%	27.84%	-93.40%	-2.71%
Cancer Precision Medical Business	747.06M	609.69M	1.13B	1.15B	271.55M
Cancer Precision Medical Business Growth	22.53%	-45.84%	-2.52%	325.28%	29.28%
Unallocated Adjustment	-294.00K	-270.00K	-238.00K	-8.50M	-50.12M
Total	750.05M	610.12M	1.13B	1.15B	332.48M
Total Growth	22.93%	-46.24%	-1.63%	246.99%	5.14%

Revenue by Geography

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	Mar '20 Mar 31, 2020	Mar '19 Mar 31, 2019	Mar '18 Mar 31, 2018	Mar '17 Mar 31, 2017	Mar '16 Mar 31, 2016
Japan	750.00M	610.00M	1.13B	1.15B	332.00M
Japan Growth	22.95%	-46.21%	-1.65%	247.29%	5.06%
Total	750.00M	610.00M	1.13B	1.15B	332.00M
Total Growth	22.95%	-46.21%	-1.65%	247.29%	5.06%

Source: S&P Global Market Intelligence.